1. Home
  2. SKWD vs MESO Comparison

SKWD vs MESO Comparison

Compare SKWD & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skyward Specialty Insurance Group Inc.

SKWD

Skyward Specialty Insurance Group Inc.

N/A

Current Price

$58.76

Market Cap

2.4B

Sector

Finance

ML Signal

N/A

Logo Mesoblast Limited

MESO

Mesoblast Limited

N/A

Current Price

$14.25

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKWD
MESO
Founded
2007
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2022
2005

Fundamental Metrics

Financial Performance
Metric
SKWD
MESO
Price
$58.76
$14.25
Analyst Decision
Buy
Buy
Analyst Count
13
3
Target Price
★ $70.45
$37.00
AVG Volume (30 Days)
★ 310.2K
192.9K
Earning Date
11-05-2026
08-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 41.81
N/A
EPS
★ 2.17
N/A
Revenue
★ $1,416,541,000.00
N/A
Revenue This Year
$39.34
$59.17
Revenue Next Year
$6.68
$59.00
P/E Ratio
$27.33
★ N/A
Revenue Growth
★ 23.16
N/A
52 Week Low
$40.60
$13.05
52 Week High
$65.69
$21.50

Technical Indicators

Market Signals
Indicator
SKWD
MESO
Relative Strength Index (RSI) 60.91 43.02
Support Level $55.18 $14.18
Resistance Level $58.81 $15.97
Average True Range (ATR) 1.47 0.37
MACD 0.59 -0.06
Stochastic Oscillator 83.12 31.30

Price Performance

Historical Comparison
SKWD
MESO

About SKWD Skyward Specialty Insurance Group Inc.

Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: